These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 27554947)

  • 1. Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage.
    Park YA; Uhm JS; Pak HN; Lee MH; Joung B
    Heart Rhythm; 2016 Sep; 13(9):1794-802. PubMed ID: 27554947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy.
    Lee YJ; Park JK; Uhm JS; Kim JY; Pak HN; Lee MH; Sung JH; Joung B
    Int J Cardiol; 2016 Jan; 203():372-8. PubMed ID: 26539960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation.
    Chan PH; Huang D; Hai JJ; Li WH; Yin LX; Chan EW; Wong IC; Lau CP; Chiang CE; Zhu J; Tse HF; Siu CW
    Heart Rhythm; 2016 Feb; 13(2):366-73. PubMed ID: 26392326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy.
    Lee SJ; Shin DH; Hwang HJ; Kim JY; Pak HN; Lee MH; Joung B
    Am J Cardiol; 2012 Aug; 110(3):373-7. PubMed ID: 22516526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation.
    Nielsen PB; Larsen TB; Skjøth F; Lip GY
    JAMA Intern Med; 2017 Apr; 177(4):563-570. PubMed ID: 28241151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control.
    Ho CW; Ho MH; Chan PH; Hai JJ; Cheung E; Yeung CY; Lau KK; Chan KH; Lau CP; Lip GY; Leung GK; Tse HF; Siu CW
    Stroke; 2015 Jan; 46(1):23-30. PubMed ID: 25406148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation.
    Genovesi S; Rossi E; Gallieni M; Stella A; Badiali F; Conte F; Pasquali S; Bertoli S; Ondei P; Bonforte G; Pozzi C; Rebora P; Valsecchi MG; Santoro A
    Nephrol Dial Transplant; 2015 Mar; 30(3):491-8. PubMed ID: 25352571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis.
    Yamashita T; Inoue H; Okumura K; Atarashi H; Origasa H;
    J Cardiol; 2015 Mar; 65(3):175-7. PubMed ID: 25169015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
    Nelson SE; Giugliano RP; Antman EM; Park JG; Norden AD; Rost NS; Silverman S; Singhal AB; Lanz HJ; Braunwald E; Ruff CT;
    J Clin Neurosci; 2021 Apr; 86():294-300. PubMed ID: 33446422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients.
    Chopard R; Piazza G; Hurwitz S; Fanikos J; Goldhaber SZ
    J Thromb Thrombolysis; 2019 Feb; 47(2):331-335. PubMed ID: 30449000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
    Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial Fibrillation: A Registry Study.
    Vestergaard AS; Skjøth F; Lip GY; Larsen TB
    Stroke; 2016 Apr; 47(4):979-85. PubMed ID: 26883499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding persistent atrial fibrillation.
    Liang JJ; Elafros MA; Mullen MT; Muser D; Hayashi T; Enriquez A; Pathak RK; Zado ES; Santangeli P; Arkles JS; Schaller RD; Supple GE; Frankel DS; Garcia FC; Deo R; Lin D; Riley MP; Nazarian S; Dixit S; Marchlinski FE; Callans DJ
    J Cardiovasc Electrophysiol; 2018 Jun; 29(6):823-832. PubMed ID: 29513397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of cerebral thromboembolic events during long-term follow-up in patients treated with transcatheter ablation for atrial fibrillation.
    Gaita F; Sardi D; Battaglia A; Gallo C; Toso E; Michielon A; Caponi D; Garberoglio L; Castagno D; Scaglione M
    Europace; 2014 Jul; 16(7):980-6. PubMed ID: 24446510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation Who Have a History of Intracranial Hemorrhage.
    Chao TF; Liu CJ; Liao JN; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chen TJ; Lip GY; Chen SA
    Circulation; 2016 Apr; 133(16):1540-7. PubMed ID: 26969761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.
    Poli D; Antonucci E; Grifoni E; Abbate R; Gensini GF; Prisco D
    J Am Coll Cardiol; 2009 Sep; 54(11):999-1002. PubMed ID: 19729116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.